24/7 Wall St. on MSN
Jim Cramer calls biotech “the hottest group in the market” as he predicts “deals are going to be flooding the market”
Quick ReadJim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B ...
Investor's Business Daily on MSN
Why this biotech, up 14% since its breakout, is on the rise once again
Pharvaris stock jumped early Monday after the FDA agreed to review the company's experimental treatment for a serious ...
Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
They have at least one thing in common: An exciting pipeline.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...
1mon
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...
Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...
Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results